1 not yet recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow MK-2750: new trials by email Literature Review of MK-2750 trials Research Report on MK-2750
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-2750 in Participants With Advanced Solid Tumors (MK-2750-002) MK-2750, 5-HT3 serotonin receptor antagonist, NK-1 receptor antagonist - Advanced Solid Tumors, Malignant Neoplasm | Phase 1 / Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 300 | 2026-11-16 | 2026-10-15 |
Neoplasms (1)
2025 (1)